Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan – amlodipine combination

References

• AbernethyDRSchwartzJBCalcium-antagonist drugsN Engl J Med199934114475710547409
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120713917679131
   PubMed Web of Science ®Google Scholar
• BasileJThe role of existing and newer calcium channel blockers in the treatment of hypertensionJ Clin Hypertens200466219
   PubMedGoogle Scholar
• BeltmanFWHeesenWFSmitAJEffects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertensionBlood Press19987109179657538
   PubMedGoogle Scholar
• ChobanianAVBakrisGLBlackHRSeventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureHypertension20034212065214656957
   PubMed Web of Science ®Google Scholar
• ChrysantSGAntihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combinationArch Intern Med1994154737438147677
   PubMed Web of Science ®Google Scholar
• ChrysantSGMelinoMKarkiSA randomized, double-blind, placebo-controlled factorial study evaluating the efficacy and safety of coadministration of amlodipine besylate (AML) plus olmesartan medoxomil (OM) compared to monotherapy in patients (PTS) with mild to severe hypertension (HTN) [abstract]J Clin Hypertens20079486
   Google Scholar
• ChrysantSGWeberMAWangACEvaluation of antihypertensive therapy with combination of olmesartan medoxomil and hydrochlorothiazideAm J Hypertens200417252915001200
   PubMed Web of Science ®Google Scholar
• CushmanWCFordCECutlerJASuccess and predictors of blood pressure control in diverse North American settings: the Antihypertensive Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)J Clin Hypertens20024393404
   PubMedGoogle Scholar
• DahlöfBDevereuxRBKjeldsenSECV morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRPrevention of CV events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• DeziiCMMedication noncompliance: what is the problem?Manag Care2000971211729418
   PubMedGoogle Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation20041101103715313950
   PubMed Web of Science ®Google Scholar
• GehiAKAliSNaBSelf-reported medication adherence and CV events in patients with stable coronary heart disease: the heart and soul studyArch Inter Med20071671798803
   PubMed Web of Science ®Google Scholar
• GilesTDOparilSSilfaniTNComparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertensionJ Clin Hypertens2007918795
   PubMedGoogle Scholar
• HajjarIKotchenTATrends in prevalence, awareness, treatment, and control of hypertension in the United States 1988–2000JAMA200329019920612851274
   PubMed Web of Science ®Google Scholar
• HasebeNKikuchiKfor the NICE Combi Study GroupControlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) StudyJ Hypertens2005234455315662234
   PubMed Web of Science ®Google Scholar
• HaworthSBathalaMSLeeJA fixed-dose combination of olmesartan medoxomil (OM) and amlodipine besylate (AM) is bioequivalent (BEQ) to free combination of the agents [abstract]Clin J Hypertens2007a9A181
   Google Scholar
• HaworthSHeyrmanRBathalaMSThe bioavailability (BAV) of a fixed-dose combination of olmesartan medoxomil (OM) and amlodipine besylate (AM) is unaffected by food [abstract]Clin J Hypertens2007b9A181
   Google Scholar
• KearneyPMWheltonMReynoldsKGlobal burden of hypertension: analysis of worldwide dataLancet20053652172315652604
   PubMed Web of Science ®Google Scholar
• JamersonKBakrisGLDählofBExceptional early blood pressure control rates: the ACCOMPLISH trialBlood Press20071680617612905
   PubMed Web of Science ®Google Scholar
• JamersonKABakrisGLWunCCRationale and design of the avoiding CV events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionAm J Hypertens20041779380115363822
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• JuliusSWeberMAKjeldsenSEThe Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapyHypertension2006483859116864741
   PubMed Web of Science ®Google Scholar
• KhalilSAElzubierAGDrug compliance among hypertensive patients in Tabuk, Saudi ArabiaJ Hypertens19971556159170010
   PubMed Web of Science ®Google Scholar
• KrumHCritical assessment of calcium antagonistsAust Fam Physician19972684159232924
   PubMedGoogle Scholar
• LaeisPPuchlerKKiechWThe pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interactionJ Hypertens200119S2132
   PubMed Web of Science ®Google Scholar
• LeenenFHWilsonTWBolliPPatterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoringCan J Cardiol199713914209374947
   PubMed Web of Science ®Google Scholar
• LewanczukRTobeSWMore medications, fewer pills: combination medications for the treatment of hypertensionCan J Cardiol200723573617534465
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236019031312493255
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPFor the collaborative study group: the effect of angiotensin-converting-enzyme inhibitor on diabetic nephropatyN Eng J Med1993329145662
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072511058717563527
   PubMed Web of Science ®Google Scholar
• MesserliFHEvolution of calcium antagonists: past, present, and futureClin Cardiol199326II12612622321
   PubMedGoogle Scholar
• MesserliFHOparilSFengZComparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertensionAm J Cardiol2000861182711090788
   PubMed Web of Science ®Google Scholar
• MichalsenAKonigGThimmeWPreventable causative factors leading to hospital admission with descompensated heart failureHeart199880437419930040
   PubMed Web of Science ®Google Scholar
• MiuraSFujinoMHanzawaHMolecular mechanism underlying inverse agonist of angiotensin II type 1 receptorJ Biol Chem2006281192889516690611
   PubMed Web of Science ®Google Scholar
• MiuraSKiyaYKanazawaTDifferential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive stateMol Endocrinol2008221394617901125
   PubMed Web of Science ®Google Scholar
• MurphyJCosterGIssues in patient complianceDrugs1997547978009421690
   PubMed Web of Science ®Google Scholar
• NeatonJDGrimmRHJrPrineasRJTreatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Research GroupJAMA1993270713248336373
   PubMed Web of Science ®Google Scholar
• NeutelJMClinical studies of CS-866, the newest angiotensin II receptor antagonistAm J Cardiol20018737C43
   PubMed Web of Science ®Google Scholar
• NeutelJMOparilSWeberMAFixed combination antihypertensive therapyHypertension: a companion to Brenner and Rector’s the kidney20052PhiladelphiaElsevier5229
   Google Scholar
• NeutelJMSmithDHWeberMAEfficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) studyJ Clin Hypertens200576416
   PubMedGoogle Scholar
• OngKLCheungBMYManYBPrevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004Hypertension200749697517159087
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSComparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertensionJ Clin Hypertens2001328391
   PubMedGoogle Scholar
• OparilSSilfaniTNWalkerJFRole of angiotensin receptor blockers as monotherapy in reaching blood pressure goalsAm J Hypertens2005182879415752958
   PubMed Web of Science ®Google Scholar
• PackerMO’ConnorCMGhaliKKEffect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study GroupN Engl J Med19963351107148813041
   PubMed Web of Science ®Google Scholar
• PaesAHBakkerASoe-AgnieCJImpact of dosage frequency on patient complianceDiabetes Care199720151279314626
   PubMed Web of Science ®Google Scholar
• PhilippTSmithTRGlazerRTwo multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertensionClin Ther2007295638017617280
   PubMed Web of Science ®Google Scholar
• PoolJLGlazerRWeinbergerMComparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsClin Ther200729617317379047
   PubMed Web of Science ®Google Scholar
• PoulterNRWedelHDahlöfBRole of blood pressure and other variables in the differential CV events rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet20053669071316154017
   PubMed Web of Science ®Google Scholar
• PrisantLMOparilSWeberMACalcium antagonistsHypertension: a companion to Brenner and Rector’s the kidney20052PhiladelphiaElsevier683704
   Google Scholar
• PrisantLMWeirMRPapademetriouVLow-dose drug combination therapy: an alternative first-line approach to hypertension treatmentAm Heart J1995130359667631621
   PubMed Web of Science ®Google Scholar
• RohatagiSHaworthSHeyrmanRLow and high doses of a fixed-dose combination of olmesartan medoxomil (OM) and amlodipine besylate (AM) are bioequivalent (BEQ) to free combination of the agents [abstract]Clin J Hypertens20079A178
   Google Scholar
• RosamondWFlegalKFurieKHeart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation2008117e2514618086926
   PubMed Web of Science ®Google Scholar
• RuddyMCKostisJBOparilSWeberMAAngiotensin II receptor antagonistsHypertension: a companion to Brenner and Rector’s the kidney20052PhiladelphiaElsevier683704
   Google Scholar
• SalazarDLeeJShenoudaMLack of pharmacokinetic (PK) drug interaction between olmesartan medoxomil (OM) and amlodipine besylate (AM) during coadministration [abstract]Clin J Hypertens20079A180
   Google Scholar
• SchwochoLMasonsonHPharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjectsJ Clin Pharmacol2001415152711361048
   PubMed Web of Science ®Google Scholar
• SicaDFixed dose combination antihypertensive drugs. Do they have a role in rational therapy?Drugs19944816247525192
   PubMed Web of Science ®Google Scholar
• SicaDRationale for fixed-dose combination in the treatment of hypertension: the cycle repeatsDrugs2002624436211827559
   PubMed Web of Science ®Google Scholar
• SmithRDYokoyamaHLevyPJNon-invasive hemodynamic data refflect treatment effects on vascular remodeling [abstract]J Clin Hypertens20079A145
   Google Scholar
• TaddeiSVirdisAGuiadoniLAntihypertensive drugs and reversing of endothelial dysfunction in hypertensionCurr Hypertens Rep20002647010981130
   PubMedGoogle Scholar
• TaylorAAShoheiberOAdherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCL versus comparable component-based therapyCongest Heart Fail200393243214688505
   PubMedGoogle Scholar
• TerpstraWFMayJFSmitAJLong-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trialJ Hypertens200119303911212974
   PubMed Web of Science ®Google Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists’ ColaborationEffects of different blood-pressure-lowering regimens on major CV events: results of prospectively-designed overviews of randomised trialsLancet200336215273514615107
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study on Antihypertensive AgentsEffects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm HgJAMA19672021028344862069
   PubMed Web of Science ®Google Scholar
• WanovichRKerrishPGerbinoBPCompliance patterns of patients treated with 2 separate antihypertensive agents versus fixed-dose combination therapy [abstract]Am J Hypertens200417223A15001195
   PubMed Web of Science ®Google Scholar
• WeirMRIzzoJLJrSicaDABlackHRCalcium antagonistsHypertension primer: the essentials of high blood pressure. Basic science, population science, and clinical management20084DallasAmerican Heart Association4659
   Google Scholar
• WeirMRDzauVJThe rennin-angiotensin-aldosterone system: a specific target for hypertension managementAm J Hypertens200112177S81
   Web of Science ®Google Scholar
• WoodhamRMOparilSLangJonesFixed low-dose antihypertensive therapyComprehensive Hypertension2007PhiladelphiaMosby Elsevierp106173
   Google Scholar